TESTOSTERONE SUCCINATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H32O5
Molecular Weight	388.4972
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC(O)=O

InChI

InChIKey=CJQNBXFUHQZFOE-VYAQIDIUSA-N

InChI=1S/C23H32O5/c1-22-11-9-15(24)13-14(22)3-4-16-17-5-6-19(23(17,2)12-10-18(16)22)28-21(27)8-7-20(25)26/h13,16-19H,3-12H2,1-2H3,(H,25,26)/t16-,17-,18-,19-,22-,23-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.google.com/patents/US20080161324 | https://www.ncbi.nlm.nih.gov/pubmed/9371446 | https://www.ncbi.nlm.nih.gov/pubmed/11717242

Testosterone succinate (Testosterone hemisuccinate) is a negatively charged derivative of Testosterone. It has being shown that Testosterone succinate induced relaxation of rat aorta, the effect was androgen structure specific and involved K+ channel activation. Testosterone succinate has being studied with respect to its antiviral activity.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
potassium ion transport 2 Target ID: GO:0006813 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11717242	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Viral infection 4 Sources: https://www.google.com/patents/US20100009970 https://www.google.com/patents/US20080161324	Primary		Basic research	Unknown Approved Use Unknown
Coronary artery disease 48 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11717242	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Skin permeation of testosterone and its ester derivatives in rats.	2000-04	10813545
Steroids as possible inhibitors of HIV-1 protease.	1998-04-16	9583617
Steroid-bovine serum albumin conjugates: molecular characterization and their interaction with androgen and estrogen receptors.	1986-05	3724140
Immobilization of ligands for affinity chromatography. Coupling on a spacer arm gel with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline as condensation agent: study of coupling conditions by means of a radioimmunologic method.	1984-11-30	6335512
Androgen modulation of adrenal angiotensin receptors.	1984-06-01	6326265
Role of steroids on the complement-induced membrane effect of septic shock.	1982-12	6186429
Influence of hormones on the release of iron by macrophages.	1981-03	7218231

Patents

Sample Use Guides

In Vivo Use Guide

Mongrel dogs: testosterone hemisuccinate in propylenglycol, 0.75 mg in 0.05 ml/kg body wt./day, for 15 days

Route of Administration: Intramuscular

In Vitro Use Guide

Rat seminal vesicles were sectioned and then incubated in MEM for 48 h, either alone (control) or in the presence of testosterone hemisuccinate (3 or 30 ng/ml), testosterone hemisuccinate-BSA (3 or 30 ng/ml), or BSA (3 ng/ml). At a normal physiological plasma concentration of testosterone (Tes) in the rat (7.72 nM), Tes-hemisuccinate (THS) increased the DNA content of rat seminal vesicles by more than twofold, whereas THS-BSA had no significant effect. These differences between THS and THS-BSA persisted at 10-fold higher concentrations (77.2 nM).

Name

Type

Language

TESTOSTERONE SUCCINATE

Preferred Name

English

Code System Code Type Description

PUBCHEM

119202